Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: α-synuclein, Nogo-A and Ubiquitin C-terminal hydrolase L1 (UCH-L1) have neuromodulatory roles for human brain. Therefore, abnormalities of these molecules are associated with neuropsychiatric disorders. Although some serum studies in the other disorders have been made, serum study of α-synuclein, Nogo-A and UCH-L1 is not present in patients with schizophrenia and healthy controls. Therefore, our aim was to compare serum levels of α-synuclein, Nogo-A and UCH-L1 of the patients with schizophrenia and healthy controls. Methods: Forty-four patients with schizophrenia who is followed by psychotic disorders unit, and 40 healthy control were included in this study. Socio-demographic form and Positive and Negative Syndrome Scale (PANSS) was applied to patients, and sociodemographic form was applied to control group. Fasting bloods were collected and the serum levels of α-synuclein, Nogo-A and UCH-L1 were measured by ELISA method. Results: Serum α-synuclein [patient: 12.73 (5.18–31.84) ng/mL; control: 41.77 (15.12–66.98) ng/mL], Nogo-A [patient: 33.58 (3.09–77.26) ng/mL; control: 286.05 (136.56–346.82) ng/mL] and UCH-L1 [patient: 5.26 (1.64–10.87) ng/mL; control: 20.48 (11.01–20.81) ng/mL] levels of the patients with schizophrenia were significianly lower than healthy controls (p<0.001). Conclusion: Our study results added new evidence for explaining the etiopathogenesis of schizophrenia on the basis of neurochemical markers.
Abstract
Objective: α-synuclein, Nogo-A and Ubiquitin C-terminal hydrolase L1 (UCH-L1) have neuromodulatory roles for human brain. Therefore, abnormalities of these molecules are associated with neuropsychiatric disorders. Although some serum studies in the other disorders have been made, serum study of α-synuclein, Nogo-A and UCH-L1 is not present in patients with schizophrenia and healthy controls. Therefore, our aim was to compare serum levels of α-synuclein, Nogo-A and UCH-L1 of the patients with schizophrenia and healthy controls. Methods: Forty-four patients with schizophrenia who is followed by psychotic disorders unit, and 40 healthy control were included in this study. Socio-demographic form and Positive and Negative Syndrome Scale (PANSS) was applied to patients, and sociodemographic form was applied to control group. Fasting bloods were collected and the serum levels of α-synuclein, Nogo-A and UCH-L1 were measured by ELISA method. Results: Serum α-synuclein [patient: 12.73 (5.18–31.84) ng/mL; control: 41.77 (15.12–66.98) ng/mL], Nogo-A [patient: 33.58 (3.09–77.26) ng/mL; control: 286.05 (136.56–346.82) ng/mL] and UCH-L1 [patient: 5.26 (1.64–10.87) ng/mL; control: 20.48 (11.01–20.81) ng/mL] levels of the patients with schizophrenia were significianly lower than healthy controls (p<0.001). Conclusion: Our study results added new evidence for explaining the etiopathogenesis of schizophrenia on the basis of neurochemical markers.
참고문헌 (46)
- Rubio MD, "Dysfunction of the ubiquitin proteasome and ubiquitin-like systems in schizophrenia", Neuropsychopharmacology, 38, pp.1910~1920 (2013)
- Lee FJ, "Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis", FASEB J, 15, pp.916~926 (2001)
- Kobayashi H, "Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis", dependence, 2004, pp.1025, 325~334
- Dao-Castellana MH, "Presynaptic dopaminergic function in the striatum of schizophrenic patients", Schizophr Res, 23, pp.167~174 (1997)
- Howes OD, "Elevated striatal dopamine function linked to prodromal signs of schizophrenia", Arch Gen Psychiatry, 66, pp.13~20 (2009)
- Siever LJ, "The pathophysiology of schizophrenia disorders : perspectives from the spectrum", Am J Psychiatry, 161, pp.398~413 (2004)
- Jellinger KA, "Lewy body", alpha-synucleinopathy in schizophrenia and depression : a preliminary neuropathological study, 2009, pp.117, 423~427
- Galvin JE, "Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease : a case for the selective vulnerability of the substantia nigra", Acta Neuropathol, 112, pp.115~126 (2006)
- Bennett MC, "The role of alpha-synuclein in neurodegenerative diseases", Pharmacol Ther, 105, pp.311~331 (2005)
- Kazantsev AG, "Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease", Arch Neurol, 65, pp.1577~1581 (2008)
- Norris EH, "Alpha-synuclein : normal function and role in neurodegenerative diseases", Curr Top Dev Biol, 60, pp.17~54 (2004)
- Singleton AB, "Altered alpha-synuclein homeostasis causing Parkinson’s disease : the potential roles of dardarin", Trends Neurosci, 28, pp.416~421 (2005)
- Al-Wandi A, "Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice", Neurobiol Aging, 31, pp.796~804 (2010)
- Scarr E, "Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder", Bipolar Disord, 8, pp.133~143 (2006)
- Schmandke A, "Nogo-A: multiple roles in CNS development, maintenance, and disease", Neuroscientist, 20, pp.372~386 (2014)
- Jitoku D, "Association study of nogo-related genes with schizophrenia in a Japanese case-control sample", Am J Med Genet B Neuropsychiatr Genet, 156, pp.581B~592B (2011)
- Sui YP, "New insights into the roles of Nogo-A in CNS biology and diseases", Neurochem Res, 40, pp.1767~1785 (2015)
- Hakak Y, "Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia", Proc Natl Acad Sci U S A, 98, pp.4746~4751 (2001)
- Tkachev D, "Oligodendrocyte dysfunction in schizophrenia and bipolar disorder", Lancet, 362, pp.798~805 (2003)
- Barley K, "Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder", Schizophr Res, 112, pp.54~64 (2009)
- Uranova N, "Electron microscopy of oligodendroglia in severe mental illness", Brain Res Bull, 55, pp.597~610 (2001)
- Schmitt A, "Altered thalamic membrane phospholipids in schizophrenia : a postmortem study", Biol Psychiatry, 56, pp.41~45 (2004)
- Shenton ME, "A review of MRI findings in schizophrenia", Schizophr Res, 49, pp.1~52 (2001)
- Wright IC, "Meta-analysis of regional brain volumes in schizophrenia", Am J Psychiatry, 157, pp.16~25 (2000)
- Coon H, "Evidence for a chromosome 2p 13-14 schizophrenia susceptibility locus in families from Palau, Micronesia", Mol Psychiatry, 3, pp.521~527 (1998)
- Novak G, "Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert", Brain Res Mol Brain Res, 107, pp.183~189 (2002)
- Tan HY, "Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans", J Clin Invest, 118, pp.2200~2208 (2008)
- Novak G, "Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA", TATC polymorphism in 3’-UTR, 2006, pp.1120, 161~171
- Ng MY, "Meta-analysis of 32 genome-wide linkage studies of schizophrenia", Mol Psychiatry, 14, pp.774~785 (2009)
- Wilkinson KD, "The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase", Science, 246, pp.670~673 (1989)
- Lewis SB, "Identification and preliminary characterization of ubiquitin C terminal hydrolase 1(UCHL1)as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage", J Neurosci Res, 88, pp.1475~1484 (2010)
- Papa L, "Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury", Crit Care Med, 38, pp.138~144 (2010)
- Mondello S, "Ubiquitin carboxyterminal hydrolase L1(UCH-L1)is increased in cerebrospinal fluid and plasma of patients after epileptic seizure", BMC Neurol, 12, pp.85~ (2012)
- Pang L, "Elevated serum ubiquitin C-terminal hydrolase-L1 levels in patients with carbon monoxide poisoning", Clin Biochem, 47, pp.72~76 (2014)
- Chalak LF, "Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy", J Pediatr, 164, pp.468~474 (2014)
- Li J, "Serum ubiquitin C-terminal hydrolase L1 as a biomarker for traumatic brain injury : a systematic review and meta-analysis", Am J Emerg Med, 33, pp.1191~1196 (2015)
- Lam YA, "Inhibition of the ubiquitin-proteasome system in Alzheimer’s disease", Proc Natl Acad Sci U S A, 97, pp.9902~9906 (2000)
- Shimura H, "Ubiquitination of a new form of alpha-synuclein by parkin from human brain : implications for Parkinson’s disease", Science, 293, pp.263~269 (2001)
- Bousman CA, "Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder : convergent pathway analysis findings from two independent samples", Am J Med Genet B Neuropsychiatr Genet, 153, pp.494~502 (2010)
- Bousman CA, "Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood", Am J Med Genet B Neuropsychiatr Genet, 153B, pp.1336~1341 (2010)
- Middleton FA, "Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia", J Neurosci, 22, pp.2718~2729 (2002)
- Altar CA, "Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts", Biol Psychiatry, 58, pp.85~96 (2005)
- Aston C, "Microarray analysis of postmortem temporal cortex from patients with schizophrenia", J Neurosci Res, 77, pp.858~866 (2004)
- Vawter MP, "Application of cDNA microarrays to examine gene expression differences in schizophrenia", Brain Res Bull, 55, pp.641~650 (2001)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders", American Psychiatric Publishing, ~ (2013)
- Kostakoğlu E, "The reliability and validity of the Turkish version of Positive and Negative Syndrome Scale(PANSS)", Turkish J Psychol, 14, pp.23~32 (1999)
